News
What's moving in strength peptides right now.
Research readouts, regulatory decisions, supply updates — translated for humans.
FDA weighs peptides-as-supplements shift amid industry push
Supplement makers urged FDA to classify peptides including BPC-157 as dietary ingredients, opening a second path to legal U.S. access separate from 503A compounding.
PeptideSciences, largest US gray-market vendor, shuts down
PeptideSciences, the largest U.S. research peptide vendor, closed March 6, 2026 as FDA enforcement, quality failures, and new legislation converged.
Sports Medicine flags safety data gaps in 12 unapproved peptides
A Sports Medicine review of 12 unapproved peptides — including MOTS-c, SS-31, and sermorelin — warns that human safety data are scarce despite promising animal evidence.
Study confirms epitalon extends telomeres in human cells
A Biogerontology study found epitalon lengthens telomeres in human cells via telomerase upregulation — the first Western mechanistic confirmation of Russian work.
FDA sets July PCAC meeting to review 7 peptides for 503A list
Twelve peptides including BPC-157 and TB-500 were dropped from FDA's Category 2 list. A July 23-24 PCAC meeting will decide whether seven can be compounded legally.
Sports medicine journals publish three injectable peptide reviews
AJSM, Sports Medicine, and Sports Health each reviewed injectable peptides in 2025-2026. All three conclude: animal data is strong, human evidence is not.
AJSM publishes first peptide therapy primer for sports medicine
USC researchers publish an AJSM primer on injectable peptide therapy, covering BPC-157, TB-500, GH secretagogues, and GHK-Cu with formal evidence grades.
FDA sets July PCAC review for 7 compounded peptides
The FDA has scheduled a July 23-24, 2026 PCAC meeting to consider adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and Emideltide to the 503A bulks list.
Health Canada warns against unauthorized injectable peptides
Health Canada issued a formal public advisory on April 9, 2026, warning against buying or injecting unauthorized peptides online, naming BPC-157 and TB-500.
HYTN spins out BPC-157 drug program into new company
HYTN Innovations is spinning its BPC-157 drug development into a new CSE-listed company aimed at refractory ligament disorders, with a CAD $1M raise.
Precision Peptide nears launch of needle-free BPC-157 patch
Precision Peptide Company says its transdermal BPC-157 patch is near commercial launch as final testing wraps — the first wearable peptide from CSE: BPC.
FDA on BPC-157: where compounding stands now
FDA's late-2023 decision on BPC-157 closed the 503A compounding pathway. Here's what changed, what it means, and what the supply chain looks like now.